The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Why MRD is a hot topic in CLL and how it should be used
Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses minimal residual disease (MRD) negativity in chronic lymphocytic leukemia (CLL) at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Dr Ghia explains that MRD is a hot topic due to the multitude of new therapies that have become available. As it is still in early stages of development, it should only be used in the context of research according to Dr Ghia.
